Leukemia, Myeloid Clinical Trial
Official title:
A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-96191 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
This Phase 1, clinical study of CC-96191 will explore the safety, tolerability and preliminary biological and clinical activity of CC-96191 as a single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML). The dose escalation (Part A) of the study will explore escalating intravenous doses of CC-96191 to estimate the MTD and/or RP2D of CC-96191 as monotherapy. The expansion (Part B), will further evaluate the safety and efficacy of CC-96191 administered at or below the MTD in one or more expansion cohorts in order to determine the RP2D.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
| Recruiting |
NCT04265963 -
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Completed |
NCT00233909 -
A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Terminated |
NCT04748848 -
A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
|
Phase 1 | |
| Completed |
NCT04039100 -
Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease
|
N/A | |
| Recruiting |
NCT03600558 -
Efficacy of FLAG Regimen for the Treatment of Patients With AML
|
||
| Completed |
NCT02538965 -
A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 2 | |
| Active, not recruiting |
NCT02333838 -
Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies
|
Phase 2 | |
| Completed |
NCT01061177 -
Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome and /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase
|
Phase 4 | |
| Completed |
NCT00025662 -
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
|
Phase 2 | |
| Terminated |
NCT02370888 -
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease
|
Phase 1 | |
| Recruiting |
NCT05805605 -
Allo HSCT Using RIC and PTCy for Hematological Diseases
|
Phase 2 | |
| Recruiting |
NCT03080922 -
High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML
|
Phase 1/Phase 2 | |
| Completed |
NCT01392989 -
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
|
Phase 2 | |
| Terminated |
NCT00306332 -
T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation
|
Phase 3 | |
| Completed |
NCT00451997 -
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes
|
Phase 2 | |
| Recruiting |
NCT04310592 -
Natural Killer Cell (CYNK-001) Infusions in Adults With AML
|
Phase 1 | |
| Recruiting |
NCT05458258 -
Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia
|
||
| Completed |
NCT00065143 -
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
|
Phase 2 | |
| Withdrawn |
NCT04406207 -
Endogenous Retroviruses in Acute Myeloid Leukemia
|